Edition:
United States

Roche Holding AG (RHHBY.PK)

RHHBY.PK on OTC Markets Group

27.76USD
30 Nov 2016
Change (% chg)

-- (--)
Prev Close
$27.76
Open
--
Day's High
--
Day's Low
--
Volume
5,936
Avg. Vol
1,049,170
52-wk High
$35.13
52-wk Low
$27.06

RHHBY.PK

Chart for RHHBY.PK

About

Roche Holding AG is a research-based healthcare company. The Company develops, manufactures and delivers medicines, and diagnostic instruments and tests. Its operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. Its Pharmaceuticals division consists of two business segments: Roche Pharmaceutical... (more)

Overall

Beta: 0.79
Market Cap(Mil.): $197,938.09
Shares Outstanding(Mil.): 6,900.50
Dividend: 1.02
Yield (%): 3.56

Financials

  RHHBY.PK Industry Sector
P/E (TTM): 21.87 29.13 29.87
EPS (TTM): 1.31 -- --
ROI: 20.05 15.56 14.95
ROE: 51.10 16.69 16.29

Amgen, Allergan apply for European nod for Avastin biosimilar

Amgen Inc and Allergan Plc said they have submitted an application to the European health regulator seeking approval of their biosimilar version of Roche Holding AG's blockbuster cancer treatment, Avastin.

9:41am EST

Pfizer's Herceptin biosimilar succeeds in key breast cancer study

Pfizer Inc said on Wednesday its experimental biosimilar of Roche Holding AG's blockbuster breast cancer treatment Herceptin was found comparable with the branded version in a key study.

Nov 30 2016

BRIEF-Patheon NV will acquire site for an immaterial sum, plus cost of associated inventory and spare parts

* Adding multimedia Patheon to acquire state-of-the-art manufacturing site

Nov 28 2016

BRIEF-Chugai, Berlin-Chemie Menarini set license agreement for PA799

* Roche's chugai and Berlin-Chemie Menarini Group announce global license agreement for an anti-cancer agent PA799 Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

Nov 28 2016

Roche announces positive results for Actemra in phase III study

VIENNA Swiss drugmaker Roche said on Sunday its rheumatoid arthritis medication Actemra for giant cell arteritis showed to be superior to steroids alone in maintaining steroid-free remission in a Phase III study.

Nov 13 2016

Roche announces positive results for Actemra in phase III study

VIENNA, Nov 13 Swiss drugmaker Roche said on Sunday its rheumatoid arthritis medication Actemra for giant cell arteritis showed to be superior to steroids alone in maintaining steroid-free remission in a Phase III study.

Nov 13 2016

Roche advances skin cancer trials as part of combination therapy strategy

ZURICH Roche is pressing ahead with two skin cancer trials that combine its immunotherapy Tecentriq with other drugs after early data showed the treatments were well-tolerated and effective in a small number of patients, the company said Monday.

Nov 07 2016

Roche advances skin cancer trials as part of combination therapy strategy

ZURICH, Nov 7 Roche is pressing ahead with two skin cancer trials that combine its immunotherapy Tecentriq with other drugs after early data showed the treatments were well-tolerated and effective in a small number of patients, the company said Monday.

Nov 07 2016

BRIEF-Roche says to hold melanoma trials based on targeted, immunotherapy approaches

* Says announces initiation of two phase iii pivotal trials in melanoma based on results of studies combining targeted and immunotherapy treatment approaches Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

Nov 07 2016

Adverse events in trial dent hopes for Roche hemophilia drug

LONDON Four patients have suffered serious adverse events in a clinical trial of an experimental hemophilia medicine from Roche, the Swiss group said on Wednesday, clouding prospects for its potential blockbuster product.

Nov 02 2016

Earnings vs. Estimates